Regulus Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Regulus Therapeutics kazanç ve gelirinin sırasıyla yıllık 22.6% ve 81.7% oranında artması tahmin edilirken, EPS'nin yıllık 9.6% oranında büyümesi bekleniyor.

Anahtar bilgiler

22.6%

Kazanç büyüme oranı

9.6%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	81.7%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	11 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:7RG0 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	N/A	-123	N/A	-59	4
12/31/2025	N/A	-85	N/A	-40	6
12/31/2024	N/A	-48	N/A	-34	6
9/30/2024	N/A	-42	-36	-36	N/A
6/30/2024	N/A	-35	-34	-33	N/A
3/31/2024	N/A	-31	-28	-27	N/A
12/31/2023	N/A	-30	-27	-27	N/A
9/30/2023	N/A	-29	-28	-27	N/A
6/30/2023	N/A	-28	-27	-27	N/A
3/31/2023	N/A	-29	-28	-27	N/A
12/31/2022	N/A	-28	-26	-26	N/A
9/30/2022	N/A	-29	-27	-27	N/A
6/30/2022	N/A	-30	-26	-26	N/A
3/31/2022	N/A	-29	-25	-25	N/A
12/31/2021	N/A	-28	-24	-24	N/A
9/30/2021	5	-22	-13	-13	N/A
6/30/2021	10	-15	-12	-12	N/A
3/31/2021	10	-16	-12	-12	N/A
12/31/2020	10	-16	-13	-13	N/A
9/30/2020	5	-19	-21	-21	N/A
6/30/2020	0	-23	-21	-21	N/A
3/31/2020	0	-21	-22	-21	N/A
12/31/2019	7	-19	-20	-20	N/A
9/30/2019	7	-22	-19	-19	N/A
6/30/2019	7	-27	-26	-26	N/A
3/31/2019	7	-36	-32	-32	N/A
12/31/2018	0	-49	-43	-43	N/A
9/30/2018	0	-55	-50	-50	N/A
6/30/2018	0	-60	N/A	-51	N/A
3/31/2018	0	-68	N/A	-56	N/A
12/31/2017	0	-72	N/A	-59	N/A
9/30/2017	0	-77	N/A	-63	N/A
6/30/2017	0	-81	N/A	-67	N/A
3/31/2017	1	-81	N/A	-67	N/A
12/31/2016	1	-82	N/A	-57	N/A
9/30/2016	12	-69	N/A	-59	N/A
6/30/2016	14	-63	N/A	-55	N/A
3/31/2016	17	-62	N/A	-48	N/A
12/31/2015	21	-56	N/A	-50	N/A
9/30/2015	14	-71	N/A	-44	N/A
6/30/2015	13	-67	N/A	-41	N/A
3/31/2015	10	-58	N/A	-42	N/A
12/31/2014	8	-57	N/A	-40	N/A
9/30/2014	9	-36	N/A	-37	N/A
6/30/2014	14	-29	N/A	-33	N/A
3/31/2014	18	-24	N/A	-30	N/A
12/31/2013	20	-19	N/A	-28	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 7RG0 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 7RG0 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 7RG0 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 7RG0 gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: 7RG0 gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 7RG0 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Regulus Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

New minor risk - Profitability

New major risk - Revenue and earnings growth

Regulus Therapeutics Inc. Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration

Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer

Regulus Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Regulus Therapeutics Inc., Annual General Meeting, May 16, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors

Regulus Therapeutics Inc. announced that it expects to receive $100 million in funding from a group of investors

Insufficient new directors

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose (Mad) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (Madpkd)

New major risk - Financial position

Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Appoints Preston S. Klassen to President and Head of Research and Development

Regulus Therapeutics Advances to Cohort 2 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces Resignation of Simos Simeonidis as Board Member

Regulus Therapeutics Inc. Announces Executive Changes

Insufficient new directors

Regulus Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022

Regulus Therapeutics Inc. Announces First Patient Dosed in Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces Positive Topline Safety and Pharmacokinetic Data from the Phase 1 Single-Ascending Dose (Sad) Clinical Trial of Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022

Insufficient new directors

Insufficient new directors

Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. Announces FDA Acceptance of Investigational New Drug Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Regulus Therapeutics Inc. to Report Q4, 2021 Results on Mar 10, 2022

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

Regulus Therapeutics Inc. Announces Successful Completion of Pre-Ind Meeting with FDA for Rgls8429

Regulus Therapeutics Inc. announced that it has received $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.

Regulus Therapeutics Inc. announced that it expects to receive $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021

Regulus Therapeutics Inc. to Present Additional Data from Its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program At PKD Connect 2021

Regulus Therapeutics Inc. Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease Program

Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Full year 2020 earnings released: US$0.45 loss per share (vs US$1.08 loss in FY 2019)

Revenue beats expectations

New 90-day high: €1.58

Regulus Therapeutics Inc. Announces Completion of Enrollment in First Cohort of Phase 1B Clinical Trial of Rgls4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Appoints Alice S. Huang to the Board of Directors

New 90-day high: €1.32

New 90-day high: €0.84

Regulus Therapeutics Collaborates with Bio-Techne Corporation for Biomarker Development

Regulus Therapeutics Inc. announced that it expects to receive $19.091813 million in funding

New 90-day high: €0.52

Revenue beats expectations

Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

New 90-day low - €0.38

New 90-day low - €0.53

First half earnings released

New 90-day high - €0.84

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin